What is the purpose of the study?

To see if abobotulinum toxin A injections can help reduce or prevent the number of migraine attacks in adults with chronic migraine.

Who can take part?

The C-BEOND Study is recruiting individuals who:

• Are aged at least 18 years
• Have been diagnosed with chronic migraine at least 12 months ago
• Started to have migraines before the age of 50 years
• Typically spend at least 15 days per month with a headache out of which at least 8 of these headache days are days with a migraine.

What will the study involve?

During the Study Treatment Period, you will be assigned to
receive one of the following:

• Dysport dose A.
• Dysport dose B.
• Placebo (a dummy injection that contains no active ingredient).

During the Extension Period, you will receive one of the following:

• Dysport dose A.
• Dysport dose B.

You cannot choose which study treatment you will receive – this will be assigned randomly by a computer. Neither you nor the study team will know which of the options you are receiving during each treatment period. This is called ‘blinding’ and is commonly used in clinical research studies to keep the results more reliable.

During a treatment session you will have injections into the muscles in your head, face, and neck. A very small quantity of your allocated study treatment will be administered with each injection.

Screening period (6-12 weeks)
Study treatment period (24 weeks)
Extension period (24 weeks)

How to take part

Email headache-research@kcl.ac.uk.

Added: 2 April 2025 | Deadline to sign up: 30 June 2025